<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39076533</PMID><DateRevised><Year>2024</Year><Month>07</Month><Day>31</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2312-0541</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Jul</Month></PubDate></JournalIssue><Title>ERJ open research</Title><ISOAbbreviation>ERJ Open Res</ISOAbbreviation></Journal><ArticleTitle>Effect of lactoferrin treatment on symptoms and physical performance in long COVID patients: a randomised, double-blind, placebo-controlled trial.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">00031-2024</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1183/23120541.00031-2024</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Long COVID is a heterogeneous condition with a variety of symptoms that persist at least 3&#x2005;months after SARS-CoV-2 infection, often with a profound impact on quality of life. Lactoferrin is an iron-binding glycoprotein with anti-inflammatory and antiviral properties. Current hypotheses regarding long COVID aetiology include ongoing immune activation, viral persistence and auto-immune dysregulation. Therefore, we hypothesised that long COVID patients may potentially benefit from lactoferrin treatment. The aims of the present study were to investigate the effect of lactoferrin on various long COVID domains: fatigue, anxiety, depression, cognitive failure and muscle strength.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We performed a randomised, double-blind, placebo-controlled trial in long COVID patients aged 18-70&#x2005;years within 12&#x2005;months after proven SARS-CoV-2 infection. Patients were randomised (1:1) to 6&#x2005;weeks of lactoferrin (1200&#x2005;mg daily) or placebo. At three hospital visits (T0, T6 and T12&#x2005;weeks), patient-reported outcome measures were collected, physical performance tests were performed and blood was drawn. The difference in fatigue at T6 was the primary outcome.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">72 participants were randomised to lactoferrin (n=36) or placebo (n=36). We found a significant decrease in fatigue, as measured with the Fatigue Assessment Scale, between T0 and T6 in both study arms, but without significant difference between the study arms (lactoferrin: 3.9, 95% CI 2.3-5.5, p=0.007; placebo: 4.1, 95% CI 2.3-5.9, p=0.013). No significant differences were found in any of the other outcomes in favour of the lactoferrin arm at T6 or T12.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Although both long COVID arms showed improved clinical outcomes at T6, the improvement did not continue until T12. Lactoferrin provided no benefit in terms of fatigue, other patient-reported outcome measures or physical functioning.</AbstractText><CopyrightInformation>Copyright &#xa9;The authors 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Redel</LastName><ForeName>Anne-Lotte</ForeName><Initials>AL</Initials><Identifier Source="ORCID">0009-0002-2990-9069</Identifier><AffiliationInfo><Affiliation>Department of Pulmonology, Franciscus Gasthuis &amp; Vlietland, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pulmonology, Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miry</LastName><ForeName>Fatana</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Pulmonology, Franciscus Gasthuis &amp; Vlietland, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hellemons</LastName><ForeName>Merel Elise</ForeName><Initials>ME</Initials><Identifier Source="ORCID">0000-0002-6666-5027</Identifier><AffiliationInfo><Affiliation>Department of Pulmonology, Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Erasmus Medical Center Transplant Institute, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oswald</LastName><ForeName>Laurien Maria Amarentia</ForeName><Initials>LMA</Initials><AffiliationInfo><Affiliation>Department of Pulmonology, Franciscus Gasthuis &amp; Vlietland, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Braunstahl</LastName><ForeName>Gerrit Johannes</ForeName><Initials>GJ</Initials><Identifier Source="ORCID">0000-0001-7671-3742</Identifier><AffiliationInfo><Affiliation>Department of Pulmonology, Franciscus Gasthuis &amp; Vlietland, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pulmonology, Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>ERJ Open Res</MedlineTA><NlmUniqueID>101671641</NlmUniqueID><ISSNLinking>2312-0541</ISSNLinking></MedlineJournalInfo><CoiStatement>Conflict of interest: A-L. Redel and F. Miry have nothing to disclose. M.E. Hellemons reports honoraria for lectures and consultancy from Boehringer Ingelheim, Pfizer and Takeda, unrelated to this study; and is an associate editor of this journal. L.M.A. Oswald reports honoraria for lectures from Stichting Medische Opleidingen. G.J. Braunstahl reports support for the present manuscript from Bonusan B.V.; honoraria for lectures and consultancy from GSK, AstraZeneca, Novartis and Sanofi Genzyme; and research grants from Sanofi Genzyme, GSK and AstraZeneca, not related to this study; and is Chairman of the NVALT Asthma Section, Secretary of the ERS Task Force on Allergy and Immunology and on the Scientific Advisory Board of Longfonds.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>3</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>30</Day><Hour>4</Hour><Minute>57</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>7</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39076533</ArticleId><ArticleId IdType="pmc">PMC11284587</ArticleId><ArticleId IdType="doi">10.1183/23120541.00031-2024</ArticleId><ArticleId IdType="pii">00031-2024</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Menges D, Ballouz T, Anagnostopoulos A, et al. . Burden of post-COVID-19 syndrome and implications for healthcare service planning: a population-based cohort study. PLoS One 2021; 16: e0254523. doi:10.1371/journal.pone.0254523</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0254523</ArticleId><ArticleId IdType="pmc">PMC8274847</ArticleId><ArticleId IdType="pubmed">34252157</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano JB, Murthy S, Marshall JC, et al. . A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis 2022; 22: e102&#x2013;e107. doi:10.1016/S1473-3099(21)00703-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, et al. . Post-acute COVID-19 syndrome. Nat Med 2021; 27: 601&#x2013;615. doi:10.1038/s41591-021-01283-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis (Lond) 2021; 53: 737&#x2013;754. doi:10.1080/23744235.2021.1924397</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/23744235.2021.1924397</ArticleId><ArticleId IdType="pmc">PMC8146298</ArticleId><ArticleId IdType="pubmed">34024217</ArticleId></ArticleIdList></Reference><Reference><Citation>Goertz YMJ, Van Herck M, Delbressine JM, et al. . Persistent symptoms 3&#x2005;months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? ERJ Open Res 2020; 6: 00542-2020. doi:10.1183/23120541.00542-2020</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/23120541.00542-2020</ArticleId><ArticleId IdType="pmc">PMC7491255</ArticleId><ArticleId IdType="pubmed">33257910</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh SP, Pritam M, Pandey B, et al. . Microstructure, pathophysiology, and potential therapeutics of COVID-19: a comprehensive review. J Med Virol 2021; 93: 275&#x2013;299. doi:10.1002/jmv.26254</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26254</ArticleId><ArticleId IdType="pmc">PMC7361355</ArticleId><ArticleId IdType="pubmed">32617987</ArticleId></ArticleIdList></Reference><Reference><Citation>Buonsenso D, Piazza M, Boner AL, et al. . Long COVID: a proposed hypothesis-driven model of viral persistence for the pathophysiology of the syndrome. Allergy Asthma Proc 2022; 43: 187&#x2013;193. doi:10.2500/aap.2022.43.220018</Citation><ArticleIdList><ArticleId IdType="doi">10.2500/aap.2022.43.220018</ArticleId><ArticleId IdType="pmc">PMC9106095</ArticleId><ArticleId IdType="pubmed">35524358</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller L, Di Benedetto S. Aged brain and neuroimmune responses to COVID-19: post-acute sequelae and modulatory effects of behavioral and nutritional interventions. Immun Ageing 2023; 20: 17. doi:10.1186/s12979-023-00341-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12979-023-00341-z</ArticleId><ArticleId IdType="pmc">PMC10090758</ArticleId><ArticleId IdType="pubmed">37046272</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, et al. . Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol 2023; 21: 133&#x2013;146. doi:10.1038/s41579-022-00846-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Romanet C, Wormser J, Fels A, et al. . Effectiveness of exercise training on the dyspnoea of individuals with long COVID: a randomised controlled multicentre trial. Ann Phys Rehabil Med 2023; 66: 101765. doi:10.1016/j.rehab.2023.101765</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rehab.2023.101765</ArticleId><ArticleId IdType="pmc">PMC10237688</ArticleId><ArticleId IdType="pubmed">37271020</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrimpf A, Braesigk A, Lippmann S, et al. . Management and treatment of long COVID symptoms in general practices: an online-based survey. Front Public Health 2022; 10: 937100. doi:10.3389/fpubh.2022.937100</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2022.937100</ArticleId><ArticleId IdType="pmc">PMC9513068</ArticleId><ArticleId IdType="pubmed">36176520</ArticleId></ArticleIdList></Reference><Reference><Citation>Nopp S, Moik F, Klok FA, et al. . Outpatient pulmonary rehabilitation in patients with long COVID improves exercise capacity, functional status, dyspnea, fatigue, and quality of life. Respiration 2022; 101: 593&#x2013;601. doi:10.1159/000522118</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000522118</ArticleId><ArticleId IdType="pmc">PMC9059007</ArticleId><ArticleId IdType="pubmed">35203084</ArticleId></ArticleIdList></Reference><Reference><Citation>Slotegraaf AI, Gerards MHG, Verburg AC, et al. . Evaluation of primary allied health care in patients recovering from COVID-19 at 6-month follow-up: Dutch nationwide prospective cohort study. JMIR Public Health Surveill 2023; 9: e44155. doi:10.2196/44155</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/44155</ArticleId><ArticleId IdType="pmc">PMC10592721</ArticleId><ArticleId IdType="pubmed">37862083</ArticleId></ArticleIdList></Reference><Reference><Citation>Drago-Serrano ME, Campos-Rodriguez R, Carrero JC, et al. . Lactoferrin: balancing ups and downs of inflammation due to microbial infections. Int J Mol Sci 2017; 18: 501. doi:10.3390/ijms18030501</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms18030501</ArticleId><ArticleId IdType="pmc">PMC5372517</ArticleId><ArticleId IdType="pubmed">28257033</ArticleId></ArticleIdList></Reference><Reference><Citation>Wakabayashi H, Oda H, Yamauchi K, et al. . Lactoferrin for prevention of common viral infections. J Infect Chemother 2014; 20: 666&#x2013;671. doi:10.1016/j.jiac.2014.08.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiac.2014.08.003</ArticleId><ArticleId IdType="pubmed">25182867</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruzel ML, Zimecki M, Actor JK. Lactoferrin in a context of inflammation-induced pathology. Front Immunol 2017; 8: 1438. doi:10.3389/fimmu.2017.01438</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01438</ArticleId><ArticleId IdType="pmc">PMC5681489</ArticleId><ArticleId IdType="pubmed">29163511</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolat E, Eker F, Kaplan M, et al. . Lactoferrin for COVID-19 prevention, treatment, and recovery. Front Nutr 2022; 9: 992733. doi:10.3389/fnut.2022.992733</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnut.2022.992733</ArticleId><ArticleId IdType="pmc">PMC9676636</ArticleId><ArticleId IdType="pubmed">36419551</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, Meng X, Zhang F, et al. . The in vitro antiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptor. Emerg Microbes Infect 2021; 10: 317&#x2013;330. doi:10.1080/22221751.2021.1888660</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2021.1888660</ArticleId><ArticleId IdType="pmc">PMC7919907</ArticleId><ArticleId IdType="pubmed">33560940</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang R, Ng TB, Sun WZ. Lactoferrin as potential preventative and adjunct treatment for COVID-19. Int J Antimicrob Agents 2020; 56: 106118. doi:10.1016/j.ijantimicag.2020.106118</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2020.106118</ArticleId><ArticleId IdType="pmc">PMC7390755</ArticleId><ArticleId IdType="pubmed">32738305</ArticleId></ArticleIdList></Reference><Reference><Citation>Campione E, Lanna C, Cosio T, et al. . Lactoferrin as antiviral treatment in COVID-19 management: preliminary evidence. Int J Environ Res Public Health 2021; 18: 10985. doi:10.3390/ijerph182010985</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph182010985</ArticleId><ArticleId IdType="pmc">PMC8535893</ArticleId><ArticleId IdType="pubmed">34682731</ArticleId></ArticleIdList></Reference><Reference><Citation>Appiah JA, Askie L, Cramond V, et al. . A clinical case definition for post COVID-19 condition in children and adolescents by expert consensus. Geneva, World Health Organization, 2023.</Citation></Reference><Reference><Citation>de Kleijn WP, De Vries J, Wijnen PA, et al. . Minimal (clinically) important differences for the Fatigue Assessment Scale in sarcoidosis. Respir Med 2011; 105: 1388&#x2013;1395. doi:10.1016/j.rmed.2011.05.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rmed.2011.05.004</ArticleId><ArticleId IdType="pubmed">21700440</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohannon RW. Muscle strength: clinical and prognostic value of hand-grip dynamometry. Curr Opin Clin Nutr Metab Care 2015; 18: 465&#x2013;470. doi:10.1097/MCO.0000000000000202</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCO.0000000000000202</ArticleId><ArticleId IdType="pubmed">26147527</ArticleId></ArticleIdList></Reference><Reference><Citation>Langius J, Visser W, Kruizenga H, et al. . Meetprotocol handknijpkracht m.b.v. Hand Dynamometer [Measurement protocol for hand grip strength using a hand dynanometer]. Nutritional Assessment Platform, 2016. Available from: https://zakboekdietetiek.nl/wp-content/uploads/2016/04/Standard-Operating-Procedure-Handknijpkdracht-NAP.pdf Date last accessed: 16 May 2024.</Citation></Reference><Reference><Citation>Ponds R, van Boxtel M, Jolles J. De 'Cognitieve Failure Questionnaire' als maat voor subjectief cognitief functioneren [The 'Cognitive Failure Questionnaire' as measurement for subjective cognitive function]. Tijdschrift voor neuropsychologie 2006; 2: 37&#x2013;45.</Citation></Reference><Reference><Citation>Scragg P, Jones A, Fauvel N. Psychological problems following ICU treatment. Anaesthesia 2001; 56: 9&#x2013;14. doi:10.1046/j.1365-2044.2001.01714.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2044.2001.01714.x</ArticleId><ArticleId IdType="pubmed">11167429</ArticleId></ArticleIdList></Reference><Reference><Citation>Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983; 67: 361&#x2013;370. doi:10.1111/j.1600-0447.1983.tb09716.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0447.1983.tb09716.x</ArticleId><ArticleId IdType="pubmed">6880820</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceban F, Ling S, Lui LMW, et al. . Fatigue and cognitive impairment in post-COVID-19 syndrome: a systematic review and meta-analysis. Brain Behav Immun 2022; 101: 93&#x2013;135. doi:10.1016/j.bbi.2021.12.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2021.12.020</ArticleId><ArticleId IdType="pmc">PMC8715665</ArticleId><ArticleId IdType="pubmed">34973396</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinmetz A, Gross S, Lehnert K, et al. . Longitudinal clinical features of post-COVID-19 patients&#x2013;symptoms, fatigue and physical function at 3- and 6-month follow-up. J Clin Med 2023; 12: 3966. doi:10.3390/jcm12123966</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm12123966</ArticleId><ArticleId IdType="pmc">PMC10299126</ArticleId><ArticleId IdType="pubmed">37373660</ArticleId></ArticleIdList></Reference><Reference><Citation>Rathi A, Jadhav SB, Shah N. A randomized controlled trial of the efficacy of systemic enzymes and probiotics in the resolution of post-COVID fatigue. Medicines (Basel) 2021; 8: 47. doi:10.3390/medicines8090047</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicines8090047</ArticleId><ArticleId IdType="pmc">PMC8472462</ArticleId><ArticleId IdType="pubmed">34564089</ArticleId></ArticleIdList></Reference><Reference><Citation>Barletta MA, Marino G, Spagnolo B, et al. . Coenzyme Q10+&#x251;-lipoic acid for chronic COVID syndrome. Clin Exp Med 2023; 23: 667&#x2013;678. doi:10.1007/s10238-022-00871-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10238-022-00871-8</ArticleId><ArticleId IdType="pmc">PMC9395797</ArticleId><ArticleId IdType="pubmed">35994177</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen KS, Mogensen TH, Agergaard J, et al. . High-dose coenzyme Q10 therapy versus placebo in patients with post COVID-19 condition: a randomized, phase 2, crossover trial. Lancet Reg Health Eur 2023; 24: 100539. doi:10.1016/j.lanepe.2022.100539</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2022.100539</ArticleId><ArticleId IdType="pmc">PMC9627534</ArticleId><ArticleId IdType="pubmed">36337437</ArticleId></ArticleIdList></Reference><Reference><Citation>Tosato M, Ciciarello F, Zazzara MB, et al. . Nutraceuticals and dietary supplements for older adults with long COVID-19. Clin Geriatr Med 2022; 38: 565&#x2013;591. doi:10.1016/j.cger.2022.04.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cger.2022.04.004</ArticleId><ArticleId IdType="pmc">PMC9212635</ArticleId><ArticleId IdType="pubmed">35868674</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Burden of Disease Long Covid Collaborators , Wulf Hanson S, Abbafati C, et al. . Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA 2022; 328: 1604&#x2013;1615. doi:10.1001/jama.2022.18931</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.18931</ArticleId><ArticleId IdType="pmc">PMC9552043</ArticleId><ArticleId IdType="pubmed">36215063</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministerie van Volksgezondheid, Welzijn en Sport . Varianten van het coronavirus SARS-CoV-2 [Variants of the coronavirus SARS-CoV-2]. Bilthoven, Rijksinstituut voor Volksgezondheid en Milieu (RIVM). https://www.rivm.nl/corona/actueel/virusvarianten#:&#x223c;:text=In%20oktober%202020%20werd%20in,als%20dominante%20virusvar iant%20in%20Nederland Date last accessed: 16 May 2024.</Citation></Reference><Reference><Citation>McCambridge J, Witton J, Elbourne DR. Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects. J Clin Epidemiol 2014; 67: 267&#x2013;277. doi:10.1016/j.jclinepi.2013.08.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2013.08.015</ArticleId><ArticleId IdType="pmc">PMC3969247</ArticleId><ArticleId IdType="pubmed">24275499</ArticleId></ArticleIdList></Reference><Reference><Citation>Geuter S, Koban L, Wager TD. The cognitive neuroscience of placebo effects: concepts, predictions, and physiology. Annu Rev Neurosci 2017; 40: 167&#x2013;188. doi:10.1146/annurev-neuro-072116-031132</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-neuro-072116-031132</ArticleId><ArticleId IdType="pubmed">28399689</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>